Physician profile
Conrad Ziembinski
NPI 1437504347
$19,115.87
in general payments reported to CMS, 2019-2025
38 companies · $3,644 in 2025
The $3,644 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $690 · 2021: $2,500 · 2022: $4,612 · 2023: $3,480 · 2024: $3,915 · 2025: $3,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,881.41 |
| Education | $157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,172.68 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $2,931.75 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $2,024.43 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,547.64 | 2021-2025 | Tremfya, Simponi, Stelara |
| Glaxosmithkline, LLC. | $1,165.75 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $1,075.24 | 2021-2025 | |
| Lilly USA, LLC | $914.98 | 2021-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $833.35 | 2020-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $821.66 | 2019-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $696.49 | 2021-2025 | Acthar |
| Pfizer INC. | $638.46 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $416.49 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $308.67 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $306.29 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $210.66 | 2023-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $149.98 | 2020-2021 | |
| Genzyme Corporation | $114.12 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $109.49 | 2022-2023 | Opsumit, Uptravi |
| Fresenius Kabi USA, LLC | $106.74 | 2023-2025 | Idacio |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Genentech USA, INC. | $56.76 | 2020-2025 | Actemra |
| Medtronic, INC. | $50.10 | 2024 | Synchromedii |
| Organon LLC | $47.08 | 2023-2025 | Hadlima |
| Alvogen INC | $39.05 | 2022-2025 | Teriparatide |
| Sobi, INC | $38.96 | 2024 | |
| Depuy Synthes Sales INC. | $33.89 | 2022-2023 | Orthovisc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.28 | 2024 | Ofev |
| Bioventus LLC | $30.76 | 2025 | Durolane |
| Bayer Healthcare Pharmaceuticals INC. | $26.47 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $25.95 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.72 | 2024 | Arcalyst |
| Tonix Medicines, INC. | $19.58 | 2025 | Tonmya |
| Teva Pharmaceuticals USA, INC. | $17.25 | 2024 | Truxima |
| Cumberland Pharmaceuticals, INC. | $16.35 | 2021 | |
| Shire North American Group INC | $14.80 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Ziembinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.